Hollow Microcapsules as Periocular Drug Depot for Sustained Release of Anti-VEGF Protein
Diseases affecting the posterior segment of the eye such as age-related macular degeneration and diabetic retinopathy are leading causes of blindness all over the world. The current treatment regimen for such diseases involves repeated intravitreal injections of anti- Vascular Endothelial Growth Factor (VEGF) proteins. This method is highly invasive and can lead to severe complications. In an attempt to develop less invasive alternatives, we propose the use of a controlled release system consisting of anti-VEGF loaded hollow microcapsules that can be administered periocularly to form drug eluting depots on the episcleral surface. The microcapsules with either positive or negative surface charge were prepared by a layer by layer approach and showed pH responsive permeability switching. An ex vivo experiment using porcine sclera indicated positively charged microcapsules remained on the episcleral surface over four days while the negatively charged microcapsules were washed away. These positively charged microcapsules were then loaded with anti-VEGF protein ranibizumab using pH dependent permeability switching and protein release from the microcapsules were studied using an in vitro setup. An ex vivo experiment utilizing porcine sclera demonstrated sustained release of ranibizumab over seven days with zero-order kinetics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Pharmaceutics - 11(2019), 7 vom: 11. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Radhakrishnan, Krishna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Age related macular degeneration |
|---|
| Anmerkungen: |
Date Revised 13.10.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/pharmaceutics11070330 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299488624 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299488624 | ||
| 003 | DE-627 | ||
| 005 | 20231225100438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pharmaceutics11070330 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0998.xml |
| 035 | |a (DE-627)NLM299488624 | ||
| 035 | |a (NLM)31336771 | ||
| 035 | |a (PII)E330 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Radhakrishnan, Krishna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hollow Microcapsules as Periocular Drug Depot for Sustained Release of Anti-VEGF Protein |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Diseases affecting the posterior segment of the eye such as age-related macular degeneration and diabetic retinopathy are leading causes of blindness all over the world. The current treatment regimen for such diseases involves repeated intravitreal injections of anti- Vascular Endothelial Growth Factor (VEGF) proteins. This method is highly invasive and can lead to severe complications. In an attempt to develop less invasive alternatives, we propose the use of a controlled release system consisting of anti-VEGF loaded hollow microcapsules that can be administered periocularly to form drug eluting depots on the episcleral surface. The microcapsules with either positive or negative surface charge were prepared by a layer by layer approach and showed pH responsive permeability switching. An ex vivo experiment using porcine sclera indicated positively charged microcapsules remained on the episcleral surface over four days while the negatively charged microcapsules were washed away. These positively charged microcapsules were then loaded with anti-VEGF protein ranibizumab using pH dependent permeability switching and protein release from the microcapsules were studied using an in vitro setup. An ex vivo experiment utilizing porcine sclera demonstrated sustained release of ranibizumab over seven days with zero-order kinetics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a age related macular degeneration | |
| 650 | 4 | |a anti-VEGF | |
| 650 | 4 | |a back of the eye | |
| 650 | 4 | |a controlled release | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a layer by layer microcapsules | |
| 650 | 4 | |a microparticles | |
| 650 | 4 | |a protein delivery | |
| 700 | 1 | |a Vincent, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, Rini Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Dickescheid, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Rupesh |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatraman, Subbu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d 2010 |g 11(2019), 7 vom: 11. Juli |w (DE-627)NLM204303303 |x 1999-4923 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:7 |g day:11 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/pharmaceutics11070330 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 7 |b 11 |c 07 | ||